GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

EKF Diagnostics Holdings EKF.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

24.40p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

EKF Diagnostics Holdings — daily EKF

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View EKF Diagnostics Holdings on TradingView ↗
Market value
£110.7m
Last close × shares
Volume
470.5k
Shares, 9 Nov 2026
Price to earnings
4535.5

About EKF Diagnostics Holdings

Its shares trade on LSE under the ticker EKF.L. It has been listed since 5 June 2002. In the fiscal year to 31 December 2025, it reported revenue of £51.6m and net income of £2.1m. At that date it held total assets of £81.1m and shareholders' equity of £69.0m.

EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm manufactures and sells diagnostic instruments, reagents and certain ancillary products. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The firm's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.

Figures and description from our data supplier, not checked against the company's own report.

More about EKF Diagnostics Holdings →

Latest on EKF Diagnostics Holdings

Our reporting

We have not reported on EKF Diagnostics Holdings yet.

Next results

30 Mar 2027

Due on 30 Mar 2027. Analysts expect earnings of 0.01 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is EKF Diagnostics Holdings's ticker?

EKF Diagnostics Holdings trades as EKF.L on LSE, under ISIN GB0031509804.

What was EKF Diagnostics Holdings's last closing price?

24.40p on 9 Nov 2026. The figure is in GBp and is never converted.

When does EKF Diagnostics Holdings next report results?

Results are expected on 30 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.